Mereo BioPharma logo

MPH - Mereo BioPharma Share Price

44.5p 0.0  0.0%

Last Trade - 10:59am

Small Cap
Market Cap £150.7m
Enterprise Value £166.8m
Revenue £n/a
Position in Universe 823rd / 1806
Unlock MPH Revenue
Relative Strength (%)
1m -1.33%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -35.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 3.20
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, Mereo BioPharma Group PLC revenues was not reported. Net loss increased 9% to £34.8M. Higher net loss reflects Administrative Expenses - Balancing valu increase of 65% to £14.3M (expense), Research & Development Expenses increase of 15% to £23.4M (expense), Interest Exp-Net of Capitalized Interes increase of 95% to £1.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for MPH
Graphical History


MPH Revenue Unlock MPH Revenue

Net Income

MPH Net Income Unlock MPH Revenue

Normalised EPS

MPH Normalised EPS Unlock MPH Revenue

PE Ratio Range

MPH PE Ratio Range Unlock MPH Revenue

Dividend Yield Range

MPH Dividend Yield Range Unlock MPH Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MPH EPS Forecasts Unlock MPH Revenue
Profile Summary

Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on development and commercialization of therapeutics for patients with rare diseases. Its pipeline includes BPS-804, MPH-966, BCT-197, BGS-649, Navicixizumab and Etigilimab. BPS-804 (setrusumab) is being developed to improve bone strength and thereby reduce fractures in the orphan disease osteogenesis imperfecta (OI). MPH-966 (alvelestat) is being developed for alpha-1 antitrypsin deficiency (AATD). BGS-649 (leflutrozole) is being developed for the treatment of obese men with hypogonadotropic hypogonadism (HH). BCT-197 (acumapimod) is being developed as a therapy for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Navicixizumab is being developed for platinum-resistant ovarian cancer. Etigilimab is being developed for advanced or metastatic solid tumors.

Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated March 10, 2015
Public Since June 9, 2016
No. of Shareholders: n/a
No. of Employees: 50
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange London Stock Exchange (AIM)
Shares in Issue 338,713,962
Free Float (0.0%)
Eligible for
MPH Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for MPH
Upcoming Events for MPH
Tuesday 29th September, 2020
Half Year 2020 Mereo BioPharma Group plc Earnings Release
Tuesday 29th September, 2020
Half Year 2020 Mereo BioPharma Group plc Earnings Call
Frequently Asked Questions for Mereo BioPharma
What is the Mereo BioPharma share price?

As of 10:59am, shares in Mereo BioPharma are trading at 44.5p, giving the company a market capitalisation of £150.7m. This share price information is delayed by 15 minutes.

How has the Mereo BioPharma share price performed this year?

Shares in Mereo BioPharma are currently trading at 44.5p and the price has moved by -26.45% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Mereo BioPharma price has moved by -8.41% over the past year.

What are the analyst and broker recommendations for Mereo BioPharma?

Of the analysts with advisory recommendations for Mereo BioPharma, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Mereo BioPharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Mereo BioPharma next release its financial results?

Mereo BioPharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Mereo BioPharma dividend yield?

Mereo BioPharma does not currently pay a dividend.

Does Mereo BioPharma pay a dividend?

Mereo BioPharma does not currently pay a dividend.

When does Mereo BioPharma next pay dividends?

Mereo BioPharma does not currently pay a dividend.

How do I buy Mereo BioPharma shares?

To buy shares in Mereo BioPharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Mereo BioPharma?

Shares in Mereo BioPharma are currently trading at 44.5p, giving the company a market capitalisation of £150.7m.

Where are Mereo BioPharma shares listed? Where are Mereo BioPharma shares listed?

Here are the trading details for Mereo BioPharma:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: MPH
What kind of share is Mereo BioPharma?

Based on an overall assessment of its quality, value and momentum, Mereo BioPharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Mereo BioPharma share price forecast 2020?

Shares in Mereo BioPharma are currently priced at 44.5p. At that level they are trading at 1.36% discount to the analyst consensus target price of 45.11.

Analysts covering Mereo BioPharma currently have a consensus Earnings Per Share (EPS) forecast of -0.093 for the next financial year.

How can I tell whether the Mereo BioPharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mereo BioPharma. Over the past six months, the relative strength of its shares against the market has been 0.110k%. At the current price of 44.5p, shares in Mereo BioPharma are trading at 33.54% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Mereo BioPharma PE Ratio?

We were not able to find PE ratio data for Mereo BioPharma.

Who are the key directors of Mereo BioPharma?

Mereo BioPharma's management team is headed by:

Peter Fellner - NEC
Denise Scots-Knight - CEO
Peter Bains - NID
Anders Ekblom - NID
Kunal Kashyap - NID
Paul Blackburn - NID
Alastair MacKinnon - CFD
John Richard - CFD
Charles Sermon - CFD
Richard Jones - CFO
Wills Hughes-Wilson - OTH
Jill Henrich - SVP
Who are the major shareholders of Mereo BioPharma?

Here are the top five shareholders of Mereo BioPharma based on the size of their shareholding:

Vivo Capital, LLC Venture Capital
Percentage owned: 11.05% (37.4m shares)
Boxer Capital, L.L.C. Hedge Fund
Percentage owned: 9.9% (33.5m shares)
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund
Percentage owned: 9.9% (33.5m shares)
Baker Bros. Advisors LP Hedge Fund
Percentage owned: 9.9% (33.5m shares)
Aspire Capital Partners, LLC Investment Advisor
Percentage owned: 6.95% (23.5m shares)
Similar to MPH
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.